Omalizumab treats multi-food allergy better than oral immunotherapy, study finds

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small amounts of common food allergens.

OIT, the most common approach to treating food allergy in the United States, involves eating gradually increasing doses of a food allergen to reduce the allergic response to it.

Of the study participants who received an extended course of omalizumab, 36% could tolerate 2 grams or more of peanut protein, or about eight peanuts, and two other food allergens by the end of the treatment period, but only 19% of participants who received multi-food OIT could do so.

Researchers attributed this difference primarily to the high rate of allergic reactions and other intolerable side effects among the participants who received OIT, leading a quarter of them to discontinue treatment. When the participants who discontinued therapy were excluded from the analysis, however, the same proportion of each group could tolerate at least 2 grams of all three food allergens.

The findings were published in an online supplement to The Journal of Allergy and Clinical Immunology and presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress in San Diego on Sunday, March 2, 2025.

“People with highly sensitive multi-food allergy previously had only one treatment option—oral immunotherapy—for reducing their allergic response to moderate amounts of those foods,” said Jeanne Marrazzo, M.D., M.P.H., director of NIH’s National Institute of Allergy and Infectious Diseases (NIAID), the study’s funder and regulatory sponsor.

“This study shows that omalizumab is a good alternative because most people tolerate it very well. Oral immunotherapy remains an effective option if treatment-related adverse effects are not an issue.”

Omalizumab works by binding to the allergy-causing antibody called immunoglobulin E in the blood and preventing it from arming key immune cells responsible for allergic reactions. This renders these cells much less sensitive to stimulation by any allergen.

The current study is the second stage of a landmark clinical trial that found a 16-week course of omalizumab increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as 1 year could consume without an allergic reaction. This next stage of the trial was designed to directly compare omalizumab with OIT for the first time.

At 10 locations across the United States, the study team enrolled 177 children and adolescents aged 1 to 17 years and three adults aged 18 to 55 years, all with confirmed allergy to less than half a peanut and similarly small amounts of at least two other common foods among milk, egg, cashew, wheat, hazelnut or walnut. After completing the first stage of the trial, 117 individuals entered the second stage of the trial.

Upon beginning Stage 2, all participants received injections of omalizumab for eight weeks. Then the participants were randomly divided in half and placed into one of two groups. Group A received omalizumab injections and multi-allergen OIT for eight weeks, while group B received omalizumab injections and placebo OIT for eight weeks.

Subsequently, group A received placebo injections and multi-allergen OIT for 44 weeks, while group B continued to receive omalizumab injections and placebo OIT for 44 weeks. Neither the participants nor the investigators knew who was in which treatment group.

Group A received omalizumab before and during their early months of OIT because data from prior studies suggested that pretreatment with the medication would significantly augment the safety of OIT, and continuing omalizumab during the early months of OIT would provide additional benefit.

During the study treatment period, 29 of 59 participants in group A discontinued therapy: 15 due to allergic reactions—some severe—or other intolerable symptoms of OIT, and 14 for other reasons, including aversion to the study foods or the burden of participating in the trial.

No participants in group B had allergic reactions or other side effects from omalizumab that led them to discontinue therapy, but seven participants in group B left the study mainly due to the burden of participating in it. In all, 30 of the original 59 members of group A (51%) and 51 of the original 58 members of group B (88%) completed treatment.

After the study treatment period, the clinical trial team tested whether the participants who completed therapy could eat at least 2 grams of peanut protein and their two other study foods without an allergic reaction.

Twenty-one of the original 58 participants in group B, or 36%, could tolerate at least 2 grams of all three foods, while only 11 of the original 59 participants in group A (the OIT-treated group), or 19%, could do so. When evaluating only the participants who completed therapy, however, the same proportion of each group could tolerate at least 2 grams of all three foods.

These results showed that omalizumab was more effective than OIT at treating multi-food allergy in people who originally had a very low tolerance to common food allergens. Investigators attributed this outcome mainly to the high rate of allergic reactions and other side effects leading to treatment discontinuation among the OIT-treated participants, despite receiving omalizumab before and during the early months of therapy.

The trial is called “Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults,” or OUtMATCH.

Further information about the OUtMATCH trial is available at ClinicalTrials.gov under study identifier NCT03881696.

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small amounts of common food allergens.

OIT, the most common approach to treating food allergy in the United States, involves eating gradually increasing doses of a food allergen to reduce the allergic response to it.

Of the study participants who received an extended course of omalizumab, 36% could tolerate 2 grams or more of peanut protein, or about eight peanuts, and two other food allergens by the end of the treatment period, but only 19% of participants who received multi-food OIT could do so.

Researchers attributed this difference primarily to the high rate of allergic reactions and other intolerable side effects among the participants who received OIT, leading a quarter of them to discontinue treatment. When the participants who discontinued therapy were excluded from the analysis, however, the same proportion of each group could tolerate at least 2 grams of all three food allergens.

The findings were published in an online supplement to The Journal of Allergy and Clinical Immunology and presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress in San Diego on Sunday, March 2, 2025.

“People with highly sensitive multi-food allergy previously had only one treatment option—oral immunotherapy—for reducing their allergic response to moderate amounts of those foods,” said Jeanne Marrazzo, M.D., M.P.H., director of NIH’s National Institute of Allergy and Infectious Diseases (NIAID), the study’s funder and regulatory sponsor.

“This study shows that omalizumab is a good alternative because most people tolerate it very well. Oral immunotherapy remains an effective option if treatment-related adverse effects are not an issue.”

Omalizumab works by binding to the allergy-causing antibody called immunoglobulin E in the blood and preventing it from arming key immune cells responsible for allergic reactions. This renders these cells much less sensitive to stimulation by any allergen.

The current study is the second stage of a landmark clinical trial that found a 16-week course of omalizumab increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as 1 year could consume without an allergic reaction. This next stage of the trial was designed to directly compare omalizumab with OIT for the first time.

At 10 locations across the United States, the study team enrolled 177 children and adolescents aged 1 to 17 years and three adults aged 18 to 55 years, all with confirmed allergy to less than half a peanut and similarly small amounts of at least two other common foods among milk, egg, cashew, wheat, hazelnut or walnut. After completing the first stage of the trial, 117 individuals entered the second stage of the trial.

Upon beginning Stage 2, all participants received injections of omalizumab for eight weeks. Then the participants were randomly divided in half and placed into one of two groups. Group A received omalizumab injections and multi-allergen OIT for eight weeks, while group B received omalizumab injections and placebo OIT for eight weeks.

Subsequently, group A received placebo injections and multi-allergen OIT for 44 weeks, while group B continued to receive omalizumab injections and placebo OIT for 44 weeks. Neither the participants nor the investigators knew who was in which treatment group.

Group A received omalizumab before and during their early months of OIT because data from prior studies suggested that pretreatment with the medication would significantly augment the safety of OIT, and continuing omalizumab during the early months of OIT would provide additional benefit.

During the study treatment period, 29 of 59 participants in group A discontinued therapy: 15 due to allergic reactions—some severe—or other intolerable symptoms of OIT, and 14 for other reasons, including aversion to the study foods or the burden of participating in the trial.

No participants in group B had allergic reactions or other side effects from omalizumab that led them to discontinue therapy, but seven participants in group B left the study mainly due to the burden of participating in it. In all, 30 of the original 59 members of group A (51%) and 51 of the original 58 members of group B (88%) completed treatment.

After the study treatment period, the clinical trial team tested whether the participants who completed therapy could eat at least 2 grams of peanut protein and their two other study foods without an allergic reaction.

Twenty-one of the original 58 participants in group B, or 36%, could tolerate at least 2 grams of all three foods, while only 11 of the original 59 participants in group A (the OIT-treated group), or 19%, could do so. When evaluating only the participants who completed therapy, however, the same proportion of each group could tolerate at least 2 grams of all three foods.

These results showed that omalizumab was more effective than OIT at treating multi-food allergy in people who originally had a very low tolerance to common food allergens. Investigators attributed this outcome mainly to the high rate of allergic reactions and other side effects leading to treatment discontinuation among the OIT-treated participants, despite receiving omalizumab before and during the early months of therapy.

The trial is called “Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults,” or OUtMATCH.

Further information about the OUtMATCH trial is available at ClinicalTrials.gov under study identifier NCT03881696.